03 Aug 2015

VIMOVO modified-release (Naproxen / Esomeprazole) - United Kingdom

ATC: M01AE
MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
PROPIONIC ACID DERIVATIVES
VIMOVO modified-release tablets

Last Updated on 03 Aug 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

VIMOVO modified-release tablets Indication

VIMOVO is indicated in adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.

 

VIMOVO modified-release tablets Generic Name

Naproxen / Esomeprazole

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - VIMOVO 500 mg/20 mg modified-release tablets (external site)

Related Learning Zones

Hypogonadism Knowledge Centre

Hypogonadism Knowledge Centre

The Hypogonadism Knowledge Centre provides healthcare professionals with free access to disease awareness sections such as epidemiology, pathophysiology, signs and symptoms, treatment options to assist the process of diagnosis, treatment and monitoring of patients with the condition. The regularly updated publications digest area contains analysis and comment on recent scientific articles related to male hypogonadism.

G.MKT.GM.MH.01.2016.0364

Type 1 Childhood Diabetes CME

Type 1 Childhood Diabetes CME

In this EACCME-accredited online CME activity Individual Patient Management in Type 1 Childhood Diabetes, healthcare professionals will learn how to assess the psychosocial wellbeing of young patients with type 1 diabetes. 

Upon successful completion of this activity, healthcare professionals (such as endocrinologists, paediatricians, paediatric endocrinologists, diabetes specialists, specialist nurses, primary care physicians) will be awarded 1 European CME credit (ECMEC).

VIMOVO modified-release Marketing Information

VIMOVO modified-release Generic Name
Naproxen / Esomeprazole
Marketing Company
AstraZeneca UK Ltd
Drug Type
POM
Date of Issue, Marketing Authority 05/11/2010

Related Drugs - Rheumatology

Back to top